News Release Details

AtriCure to Participate in Upcoming Investor Conferences

October 22, 2018 at 4:01 PM EDT

MASON, Ohio--(BUSINESS WIRE)--Oct. 22, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences.

AtriCure is scheduled to present at the Stifel 2018 Healthcare Conference in New York City on Wednesday, November 14, 2018. Management is scheduled to present at 1:15 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at A replay of the presentation will be available for 90 days following the presentation.

AtriCure is scheduled to host investor meetings at the Canaccord Genuity 12th Annual Medical Technologies and Diagnostics Forum in New York City on Thursday, November 15, 2018.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide, with more than 150,000 implanted to date. For more information, visit or follow us on Twitter @AtriCure.

Source: AtriCure, Inc.

AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice President and Chief Financial Officer
Gilmartin Group
Lynn Pieper Lewis, 415-937-5402
Investor Relations